Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure

Emerging Infectious Diseases

Volumn 15, Issue 7, 2009, Pages 1068-1076

  Howard, Susan J ^a,b   Cerar, Dasa ^c   Anderson, Michael J ^b   Albarrag, Ahmed ^b   Fisher, Matthew C ^d   Pasqualotto, Alessandro C ^e   Laverdiere, Michel ^f   Arendrup, Maiken C ^g   Perlin, David S ^h   Denning, David W ^a,b,i  

^a Regional Mycology Laboratory   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^g STATENS SERUM INSTITUT   (Denmark)

^h PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

ⁱ MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; MICROSATELLITE DNA; POSACONAZOLE; PYRROLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CLINICAL ARTICLE; CROSS RESISTANCE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; NUCLEOTIDE SEQUENCE; TREATMENT FAILURE;

AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE PROGRESSION; DRUG RESISTANCE, FUNGAL; EVOLUTION, MOLECULAR; FUNGAL PROTEINS; HUMANS; ITRACONAZOLE; PYRIMIDINES; TREATMENT FAILURE; TRIAZOLES;

EID: 67650657544     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1507.090043     Document Type: Article

References (40)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781-803. DOI: 10.1086/513943
2. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-60. DOI: 10.1086/525258
3. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs. 2007;67:1567-601. DOI: 10.2165/00003495-200767110-00004
4. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997;41:1364-8.
5. Dannaoui E, Borel E, Monier MF, Piens MA, Picot S, Persat F. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother. 2001;47:333-40. DOI: 10.1093/jac/47.3.333
6. Chen J, Li H, Li R, Bu D, Wan Z. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother. 2004;55:31-7. DOI: 10.1093/jac/dkh507
7. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, et al. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents. 2006;28:450-3. DOI: 10.1016/j.ijantimicag.2006.08.017
8. Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B acquired resistance to itraconazole. Scand J Infect Dis. 1997;29:509-12.
9. Warris A, Weemaes CM, Verweij PE. Multidrug resistance in Aspergillus fumigatus. N Engl J Med. 2002;347:2173a-4. DOI: 10.1056/ NEJM200212263472618
10. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2003;47:1120-4. DOI: 10.1128/ AAC.47.3.1120-1124.2003
11. Nascimento AM, Goldman GH, Park S, Marras SA, Delmas G, Oza U, et al. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother. 2003;47:1719-26. DOI: 10.1128/ AAC.47.5.1719-1726.2003
12. Balashov SV, Gardiner R, Park S, Perlin DS. Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the cyp51A gene of Aspergillus fumigatus that confer resistance to itraconazole. J Clin Microbiol. 2005;43:214-22. DOI: 10.1128/ JCM.43.1.214-222.2005
13. Mann PA, Parmegiani RM, Wei SQ, Mendrick CA, Li X, Loebenberg D, et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother. 2003;47:577-81. DOI: 10.1128/AAC.47.2.577-581.2003
14. da Silva Ferreira ME, Capellaro JL, dos Reis Marques E, Malavazi I, Perlin D, Park S, et al. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother. 2004;48:4405-13. DOI: 10.1128/ AAC.48.11.4405-4413. 2004
15. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother. 2004;48:2747-50. DOI: 10.1128/ AAC.48.7.2747-2750.2004
16. Mellado E, Alcazar-Fuoli L, Garcia-Effron G, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. New resistance mechanisms to azole drugs in Aspergillus fumigatus and emergence of antifungal drugs-resistant A. fumigatus atypical strains. Med Mycol. 2006;44(Suppl):367-71. DOI: 10.1080/13693780600902243
17. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51:1897-904. DOI: 10.1128/AAC.01092-06
18. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356:1481-3. DOI: 10.1056/ NEJMc061720
19. Moore CB, Sayers N, Mosquera J, Slaven J, Denning DW. Antifungal drug resistance in Aspergillus. J Infect. 2000;41:203-20. DOI: 10.1053/jinf.2000.0747
20. Mowat E, Warn P, Denning D, Fitzpatrick W, Patterson T, Jones B, et al. The potential role of Afumdr4 in azole resistance during Aspergillus fumigatus multicellular growth. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008 Oct 25-28; Washington, DC. Abstract M-2190.
21. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee on Antimicrobial Susceptibility Testing EUCAST. EUCAST technical note on method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect. 2008;14:982-4. DOI: 10.1111/j.1469-0691.2008.02086.x
22. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monzon A, Cuenca-Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother. 2008;52:2468-72. DOI: 10.1128/AAC.00156-08
23. Verweij PE, Howard SJ, Melchers WJG, Denning DW. Azole resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updates. In press.
24. de Valk HA, Meis JF, Curfs IM, Muehlethaler K, Mouton JW, Klaassen CH. Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J Clin Microbiol. 2005;43:4112-20. DOI: 10.1128/JCM.43.8.4112-4120.2005
25. Pasqualotto AC, Denning DW, Anderson MJ. A cautionary tale: lack of consistency in allele sizes between two laboratories for a published multilocus microsatellite typing system. J Clin Microbiol. 2007;45:522-8. DOI: 10.1128/JCM.02136-06
26. Bowcock AM, Ruiz-Linares A, Tomfohrde J, Minch E, Kidd JR, Cavalli-Sforza LL. High resolution of human evolutionary trees with polymorphic microsatellites. Nature. 1994;368:455-7. DOI: 10.1038/368455a0
27. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. Document M38-A2. 2002.
28. Gomez-Lopez A, Garcia-Effron G, Mellado E, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M. In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother. 2003;47:3085-8. DOI: 10.1128/AAC.47.10.3085-3088.2003
29. Dannaoui E, Persat F, Monier MF, Borel E, Piens MA, Picot S. In vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother. 1999;44:553-5. DOI: 10.1093/jac/44.4.553
30. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol. 2008;46:2568-72. DOI: 10.1128/JCM.00535-08
31. Verweij PE, Te Dorsthorst DT, Rijs AJ, De Vries-Hospers HG, Meis JF. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol. 2002;40:2648-50. DOI: 10.1128/JCM.40.7.2648-2650.2002
32. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:e219. DOI: 10.1371/journal.pmed. 0050219
33. van der Linden JW, Jansen RR, Bresters D, Visser CE, Geerlings SE, Kuijper EJ, et al. Azole-resistant central nervous system aspergillosis. Clin Infect Dis. 2009;48:1111-3. DOI: 10.1086/597465
34. Manavathu EK, Espinel-Ingroff A, Alangaden G, Chandrasekar PH. Molecular studies on voriconazole-resistance in a clinical isolate of Aspergillus fumigatus. In: Proceedings of 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago, IL, USA. Abstract M-392.
35. Manavathu EK, Baskaran I, Krishnan S, Alangaden G, Chandrasekar PH. Cytochrome P450 14-alpha-sterol demethylase mutation dependent triazole cross-resistance in Aspergillus fumigatus. In: Proceedings of 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; 2003 Sep 14-17. Abstract M-471.
36. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother. 2004;48:568-74. DOI: 10.1128/AAC.48.2.568-574.2004
37. Coste A, Selmecki A, Forche A, Diogo D, Bougnoux ME, d'Enfert C, et al. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell. 2007;6:1889-904. DOI: 10.1128/EC.00151-07
38. Tucker RM, Williams PL, Arathoon EG, Stevens DA. Treatment of mycoses with itraconazole. Ann N Y Acad Sci. 1988;544:451-70. DOI: 10.1111/j.1749-6632. 1988.tb40443.x
39. Law D, Moore CB, Denning DW. Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrob Agents Chemother. 1994;38:1561-6.
40. Pasqualotto AC, Denning DW. Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. Int J Antimicrob Agents. 2007;30:93-4. DOI: 10.1016/j.ijantimicag.2006.11.027